



REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/125,114
Filing Date	August 18, 1998
First Named Inventor	PRICE
Group Art Unit	1617
Examiner Name	A. Berman
Attorney Docket Number	108129-08004

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
AUG 15 2002
1600 1200

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to application Examination and Provisions Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114

a. Previously submitted

i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on May 16, 2002
(Any unentered amendment(s) referred to above will be entered).

ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

iii. Other: _____

b. Enclosed

i. Preliminary Amendment/Reply

ii. Affidavit(s)/Declaration(s)

iii. Information Disclosure Statement (IDS)

iv. Other: _____

2. Miscellaneous

a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)

b. Other: _____

3. Fees

The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

a. The Director is hereby authorized to charge any deficiency in the following fees or credit any overpayments to Deposit Account No. 01-2300

i. RCE fee required under 37 C.F.R. § 1.17(e) 08/14/2002 ASONDAF1 00000131 09125114

ii. Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) 01 FC:179 740.00 0P

iii. Other: _____

b. Check No. 344664 in the amount of \$1550.00.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Robert K. Carpenter	Registration No. (Attorney/Agent)	34,794
Signature		Date	August 12, 2002

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:

Name (Print/Type)	
Signature	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

RKC:tdd #130492-1



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

PRICE

Art Unit: 1617

Application No.: 09/125,114

Examiner: A. Berman

Filed: August 18, 1998

Attorney Dkt. No.: 108129-08004

For: DOSAGE FORM OF IBUPROFEN

PRELIMINARY AMENDMENT WITH FILING OF RCE

Commissioner for Patents
Washington, D.C. 20231

August 12, 2002

Sir:

Prior to continued examination of the above-identified patent application, please amend the application as follows:

IN THE CLAIMS:

Please cancel claims 27-29 and 38 without prejudice to or disclaimer of the subject matter contained therein.

Please amend claims 1, 16 and 26 as follows:

1. (Amended) A solid non-effervescent compressed dosage form suitable for oral administration comprising a homogenous admixture of a racemic ibuprofen medicament present to an extent of 35% or more by weight of the dosage form and a carrier material comprising

[Handwritten mark: a large 'F' with a bracket underneath, and 'G' written next to it.]

RECEIVED
AUG 15 2002
TECH CENTER 1600/2900

#33/F
AKD
8-16-02